Technology Alcohol Use Disorder Is the Largest Untreated Market in Addiction Care. Three Medications Have Been Approved for Years, and Almost No One Receives Them. While institutional capital and policy reform have spent a decade transforming the opioid treatment landscape, the nation's most prevalent substance use disorder remains virtually untouched by modern ... Read More Featured Healthcare Articles Regulation Wyoming Medicaid ABA Runs on Two Tracks, and Only the DD Waiver Rate Was Cut. A Pandemic Funding Cliff Dropped 97153 to $7.00, and a July 2026 Schedule Restored It to $19.23. Read More Technology Xylazine and Medetomidine Are Rewriting What Overdose Looks Like. Naloxone Reverses the Opioid and the Patient Still Will Not Wake Up. Read More M&A Verbal Beginnings RBTs in Rockville Struck July 20 Over a First Contract. The Standoff May Come Down to Reimbursement, Not Just Bargaining. Read More Blog Medicaid Reentry Waivers Are Opening a New Market in Addiction Care. The Weeks After Release Are the Deadliest for Overdose, and Coverage Now Reaches Through the Gate. Read More Get the Latest Behavioral Health News and Articles Direct to Your Inbox Email Latest Articles Regulation Value-Based Care in Behavioral Health Lives on the Floor, Not in the Binder. Here Is What Separates the Programs That Work. Read More Technology Contingency Management Is the Only Proven Treatment for Stimulant Use Disorder. Paying Patients to Get Better Is Still Hard to Fund, and Harder to Do Legally. Read More Regulation Alaska Medicaid ABA Rates Jumped Roughly 41 Percent on July 1, 2026, Lifting the State to the Top of the Regional Range. A Guidehouse Rate Study, Not Inflation, Reset the Numbers. Read More Blog GLP-1 Drugs for Addiction Are Moving From Anecdote to Evidence. A 2026 Trial Suggests Semaglutide Can Blunt the Urge to Drink. Read More Technology Alcohol Use Disorder Is the Largest Untreated Market in Addiction Care. Three Medications Have Been Approved for Years, and Almost No One Receives Them. Read More Regulation Wyoming Medicaid ABA Runs on Two Tracks, and Only the DD Waiver Rate Was Cut. A Pandemic Funding Cliff Dropped 97153 to $7.00, and a July 2026 Schedule Restored It to $19.23. Read More Technology Xylazine and Medetomidine Are Rewriting What Overdose Looks Like. Naloxone Reverses the Opioid and the Patient Still Will Not Wake Up. Read More M&A Verbal Beginnings RBTs in Rockville Struck July 20 Over a First Contract. The Standoff May Come Down to Reimbursement, Not Just Bargaining. Read More Article Categories M&A Technology Regulation
Technology Alcohol Use Disorder Is the Largest Untreated Market in Addiction Care. Three Medications Have Been Approved for Years, and Almost No One Receives Them. While institutional capital and policy reform have spent a decade transforming the opioid treatment landscape, the nation's most prevalent substance use disorder remains virtually untouched by modern ... Read More
Regulation Wyoming Medicaid ABA Runs on Two Tracks, and Only the DD Waiver Rate Was Cut. A Pandemic Funding Cliff Dropped 97153 to $7.00, and a July 2026 Schedule Restored It to $19.23. Read More
Technology Xylazine and Medetomidine Are Rewriting What Overdose Looks Like. Naloxone Reverses the Opioid and the Patient Still Will Not Wake Up. Read More
M&A Verbal Beginnings RBTs in Rockville Struck July 20 Over a First Contract. The Standoff May Come Down to Reimbursement, Not Just Bargaining. Read More
Blog Medicaid Reentry Waivers Are Opening a New Market in Addiction Care. The Weeks After Release Are the Deadliest for Overdose, and Coverage Now Reaches Through the Gate. Read More
Regulation Value-Based Care in Behavioral Health Lives on the Floor, Not in the Binder. Here Is What Separates the Programs That Work. Read More
Technology Contingency Management Is the Only Proven Treatment for Stimulant Use Disorder. Paying Patients to Get Better Is Still Hard to Fund, and Harder to Do Legally. Read More
Regulation Alaska Medicaid ABA Rates Jumped Roughly 41 Percent on July 1, 2026, Lifting the State to the Top of the Regional Range. A Guidehouse Rate Study, Not Inflation, Reset the Numbers. Read More
Blog GLP-1 Drugs for Addiction Are Moving From Anecdote to Evidence. A 2026 Trial Suggests Semaglutide Can Blunt the Urge to Drink. Read More
Technology Alcohol Use Disorder Is the Largest Untreated Market in Addiction Care. Three Medications Have Been Approved for Years, and Almost No One Receives Them. Read More
Regulation Wyoming Medicaid ABA Runs on Two Tracks, and Only the DD Waiver Rate Was Cut. A Pandemic Funding Cliff Dropped 97153 to $7.00, and a July 2026 Schedule Restored It to $19.23. Read More
Technology Xylazine and Medetomidine Are Rewriting What Overdose Looks Like. Naloxone Reverses the Opioid and the Patient Still Will Not Wake Up. Read More
M&A Verbal Beginnings RBTs in Rockville Struck July 20 Over a First Contract. The Standoff May Come Down to Reimbursement, Not Just Bargaining. Read More